PTAB Upholds Breast Cancer Treatment Drug Patent

Oct 29, 2015

Reading Time : 1 min

The ’856 patent, owned by ImmunoGen Inc., covers the drug, Kadcyla, which is used to treat HER2-positive metastatic breast cancer. The ’856 patent claims an immunoconjugate comprised of Herceptin, which is a humanized form of a mouse monoclonal antibody, and a maytansinoid, which has cytotoxic properties. Phigenix argued that the claims of the ’856 patent were obvious in light of a prior art reference, Chari 1992. Chari 1992 also discloses an immunoconjugate of a humanized form of a mouse monoclonal antibody and a maytansinoid. Petitioner argued that it would have been obvious to substitute Herceptin for the antibody disclosed in Chari 1992. ImmunoGen contended that at the time the ’856 patent was filed in March 2000, Herceptin-maytansinoid immunoconjugates would have been expected to cause toxicity in the patient’s liver. The PTAB ruled that, given the references disclosing the toxic effect that would have been expected from a Herceptin-maytansinoid immunoconjugate, it would not have been obvious to an ordinary artisan to substitute the Chari 1992 antibody with Herceptin. 

Phigenix had also filed a petition seeking inter partes review of U.S. Patent No. 7,097,840, which was also a patent for Kadcyla. The PTAB declined to institute review in that case, finding that it was unlikely that Phigenix would prevail on its claims.

Phigenix, Inc. v. ImmunoGen, Inc., IPR2014-00676, Paper No. 39, (PTAB Oct. 27, 2015).

Share This Insight

Previous Entries

IP Newsflash

November 17,2025

The district of Delaware recently denied a defendant’s partial motion to dismiss pre-suit willful infringement from the litigation, finding instead that the allegations taken as a whole were sufficient to support pre-suit willfulness at the pleading stage. Specifically, the court found that the allegations as to the defendant’s involvement in a related foreign opposition proceeding and participation in the relevant industry were accompanied by detailed factual support that sufficiently pleaded willful infringement for the pre-suit period.

...

Read More

IP Newsflash

November 14, 2025

The Ninth Circuit recently reversed a district court’s decision to strike a plaintiff’s trade secret claims under the Defend Trade Secrets Act (DTSA) at the discovery stage. In doing so, the Ninth Circuit made clear that under the DTSA, whether a party defined their trade secret with sufficient particularity is a question of fact that generally does not lend itself to resolution in the absence of at least some discovery. This ruling contrasts with the California Uniform Trade Secrets Act (CUTSA), which requires a party to define their trade secrets with reasonable particularity before commencing discovery.

...

Read More

IP Newsflash

November 11, 2025

The Federal Circuit recently vacated a summary judgment ruling of invalidity, holding that the district court erred in applying preclusive effect to the Patent Trial and Appeal Board’s unpatentability findings regarding other claims in the same patent. In doing so, the Federal Circuit reiterated that issue preclusion does not apply where the prior factual determinations were made under a lower standard of proof.

...

Read More

IP Newsflash

November 3, 2025

The Federal Circuit recently clarified the requirement for work disclosed in a reference to qualify as “by another” under pre-AIA Sections 102(a) and (e), holding that there must be complete inventive identity between the information disclosed in the asserted reference and the inventors named on the relevant patent. 

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.